Caffeine increases POAG risk

Article

High caffeine intake is associated with an increased risk of high-tension primary open angle glaucoma (POAG) in subjects with a positive family history of glaucoma, according to a study published in the May 2008 issue of Investigative Ophthalmology & Visual Science.

High caffeine intake is associated with an increased risk of high-tension primary open angle glaucoma (POAG) in subjects with a positive family history of glaucoma, according to a study published in the May 2008 issue of Investigative Ophthalmology & Visual Science.

Jae Hee Kang, ScD of Harvard Medical School, US and colleagues observed subjects aged ≥40 years without POAG to determine if caffeine, which raises intraocular pressure (IOP), is also associated with an increased risk of POAG.

Of the 121,172 subjects monitored and followed-up with questionnaires between 1980 and 2004, 1011 POAG cases were confirmed. The researchers found that higher levels of caffeinated coffee intake correlated with increased risk of POAG, particularly POAG with elevated IOP, in those with a family history of glaucoma.

Compared with an intake of ≤150 mg/day, consumption of 150–299 mg/d was associated with a 1.05 increased risk; for 300–449 mg/d, risk increased 1.19 times; consuming 450–599 mg/d carried a 1.13 greater risk; for ≥600 mg/d, risk increased 1.17 times. Where ≥5 cups of caffeinated coffee were consumed daily, the risk was 1.61 times greater. Consumption of tea and caffeinated cola did not correlate with an increased risk.

Greater caffeine intake was associated with elevated POAG risk only in those with positive family histories of glaucoma. The researchers concluded that these results warrant further study, as the apparent increased risk may be an accident of chance rather than a concrete correlation.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.